ProMIS Neurosciences, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutic antibodies and vaccines targeting toxic misfolded proteins implicated in neurodegenerative diseases and other misfolded protein disorders. Its core products include PMN310, a humanized IgG1 monoclonal antibody targeting toxic amyloid beta oligomers for the treatment of Alzheimer's disease; PMN267, an antibody in preclinical development targeting misfolded TDP-43 for amyotrophic lateral sclerosis (ALS); PMN442, a monoclonal antibody targeting toxic alpha-synuclein oligomers and seeding fibrils for multiple system atrophy and related synucleinopathies; and PNM440, an alpha-synuclein vaccine for multiple synucleinopathies. The company also develops PMN311, an amyloid-beta vaccine candidate for Alzheimer's disease, and pursues therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. ProMIS applies proprietary computational platforms, including the EpiSelect™ engine, to predict and identify disease-specific epitopes on misfolded protein oligomers to develop targeted therapeutics. The company operates primarily in Canada and the United States and was founded in 2005, with headquarters in Toronto, Ontario. Recent major developments include advancing the PMN310 antibody through a Phase 1b clinical trial for Alzheimer’s disease, which is over 85% enrolled with cohorts 1 and 2 fully enrolled, showing a favorable safety profile and on track to report interim six-month data in Q2 2026 and top-line 12-month results in Q4 2026. The Data and Safety Monitoring Board has recommended progressing to the third and final dose escalation cohort of PMN310. In 2024 and 2025, ProMIS secured significant financing, including a $30.3 million private placement as part of up to $122.7 million in funding to support clinical development and general corporate purposes, and a $2.4 million PIPE financing in mid-2025. Additionally, in November 2025, the company executed a 1-for-25 reverse stock split to meet Nasdaq bid price requirements. These operational and financial advancements position ProMIS to deliver on its promise of developing disease-modifying therapies for Alzheimer’s, ALS, and synucleinopathies using its innovative epitope-targeting antibody and vaccine platform technology. The company actively participates in healthcare investor forums and continues its research collaborations and clinical development activities in North America.
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
Wall Street Analysts See a 230.23% Upside in Promis Neurosciences (PMN): Can the Stock Really Move This High?
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet
GMG Applies for Additional Environmental Approvals to Produce Graphene in USA
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
ProMIS Neurosciences to Participate in Upcoming Conferences in June
ProMIS Neurosciences to Participate in Upcoming Conferences in June
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
Promis Neurosciences (PMN) to Release Earnings on Monday
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)
Ally Bridge Group NY LLC Increases Holdings in Promis Neurosciences $PMN
Promis Neurosciences (NASDAQ:PMN) Given Consensus Rating of “Moderate Buy” by Brokerages
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Promis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy” from Brokerages